Ovarian Cancer Clinical Trial
Official title:
A Randomized Phase III Study for the Treatment of Recurrent Epithelial Ovarian Cancer: Chemotherapy Alone Versus Chemotherapy Followed by Secondary Cytoreductive Surgery in Patients With a Treatment-Free Interval of More Than 12 Months
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor
so that it can be removed during surgery.
PURPOSE: Randomized phase III trial to study the effectiveness of chemotherapy with or
without surgery in treating patients who have recurrent epithelial ovarian cancer.
OBJECTIVES:
- Compare survival and progression free survival in patients with ovarian epithelial
cancer after receiving treatment with chemotherapy with or without secondary
cytoreductive surgery.
- Determine the toxicity of these treatment regimens in these patients.
- Determine the complications related to surgical treatment in these patients.
- Compare the quality of life in these patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to stage
at initial diagnosis (early stage I-IIa vs advanced stage IIb-IV), length of interval from
end of prior first line chemotherapy (1-2 years vs more than 2 years), response to first 3
courses of second line induction chemotherapy in this study (no change vs partial remission
vs complete remission), number of measurable tumor lesions (1 vs more than 1), largest tumor
size of recurrence (less than 5 cm vs 5 cm or more), and participating center.
Patients receive second line induction chemotherapy with either 3 courses of a 3-4 week
regimen or 6 courses of a weekly regimen of platinum based (cisplatin or carboplatin)
therapy. Patients with no change, partial remission, or complete remission are randomized to
one of two treatment arms.
- Arm I: Patients undergo secondary cytoreductive surgery within 14 days of
randomization. Within 8 weeks after the last preoperative chemotherapy course, patients
continue platinum based chemotherapy every 3-4 weeks for at least 3 additional courses
in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients continue platinum based chemotherapy for at least 3 additional courses
as in arm I.
Quality of life is assessed at baseline; before the 4th or 6th course of chemotherapy or 1
week before surgery; after the 6th course of chemotherapy in the chemotherapy only arm OR
before the 4th or 6th course of chemotherapy in the surgery arm; 2 months after chemotherapy
or after the 6th course of chemotherapy in the surgery arm; and then every 6 months for up
to 5 years.
Patients are followed every 3 months for 2 years, and then every 6 months for 3 years or
until disease progression.
PROJECTED ACCRUAL: Approximately 700 patients will be accrued for this study within 5 years.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |